Iterum Therapeutics (ITRM) Fundamental Analysis: Revenue, Earnings & Valuation

5.12 / 10

Netural

Fundamental analysis rates the stock neutral (5.1/10). Strengths include a solid interest coverage ratio and positive Asset‑MV, but long‑term debt relative to working capital and other ratios raise concerns. Overall, the fundamentals suggest cautious positioning.

Analysis Checks(9/10)

Revenue-MV

Value-2.71

Score3/3

Weight31.15%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.43%

1M Return0.13%

Inventory turnover ratio

Value0.03

Score2/3

Weight-3.55%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value16.12

Score3/3

Weight5.79%

1M Return1.67%

PB-ROE

Value-0.35

Score2/3

Weight29.06%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value4.58

Score1/3

Weight-2.09%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-3.61%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value5.13

Score2/3

Weight-3.41%

1M Return-1.13%

Asset-MV

Value-0.49

Score2/3

Weight46.07%

1M Return11.12%

Is ITRM fundamentally strong?

ITRM scores 5.12/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -0.08 P/E ratio, -0.25 P/B ratio, and 63.82% earnings growth, these metrics solidify its Netural investment rating.